FrancophonIA/ELRC3.0 huggingface dataset:
English: Contact your doctor or go to your nearest emergency center immediately if you experience any of the following side effects: - severe allergy to mexiletine (with symptoms such as severe rash with fever); this is a very rare side effect, may affect up to 1 in 10,000 people.
Slovenian: Če se pojavi kateri koli izmed teh neželenih učinkov, takoj obvestite svojega zdravnika ali obiščite najbližji center za nujno medicinsko pomoč: - huda alergija na meksiletin (s simptomi, kot je hud izpuščaj z vročino); to je zelo redek neželeni učinek, ki se pojavi pri največ 1 od 10.000 bolnikov., - motnje srčnega ritma, za simptome in dodatne informacije glejte poglavje »Opozorila in previdnostni ukrepi«; to je pogost neželeni učinek, ki se lahko pojavi pri največ 1 od 10
English: Not known: hallucinations, confusional state Nervous system disorders
Slovenian: Neznana: halucinacije, zmedenost
English: • HCPs should counsel patients on: o The risk of cardiac arrhythmias (informing about symptoms of arrhythmias, advising patients to contact immediately their HCP, or emergency centres, if they experience any of these symptoms);
Slovenian: • Zdravstveni delavci se morajo z bolniki posvetovati o: o tveganju za srčne aritmije (obvestiti jih morajo o simptomih aritmij in jim svetovati, da takoj obvestijo svojega zdravnika ali center za nujno medicinsko pomoč, če se ti simptomi pojavijo); o tveganju za zmanjšanje očistka zdravila Namuscla pri bolnikih z jetrno okvaro (svetovati jim morajo, da obvestijo svojega zdravnika, če imajo obstoječo jetrno bolezen);
English: Co-administration of mexiletine and antiarrhythmics inducing torsades de pointes (class Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant) increases the risk of potentially lethal torsades de pointes.
Slovenian: Sočasno jemanje meksiletina in antiaritmikov, ki inducirajo aritmije torsades de pointes (razred Ia: kinidin, prokainamid, dizopiramid, ajmalin; razred Ic: enkainid, flekainid, propafenon, moricizin; razred III: amiodaron, sotalol, ibutilid, dofetilid, dronedaron, vernakalant) poveča tveganje za potencialno smrtne aritmije torsades de pointes.
English: o In patients with cardiac abnormalities, and in patients prone to such abnormalities, a detailed cardiac evaluation (including ECG) should be carried out before and after any dose increase.
Slovenian: o Pri bolnikih s srčnimi nepravilnostmi in tistih, ki so dovzetni za take nepravilnosti, je treba pred vsakim zvišanjem odmerka in po njem opraviti podroben pregled srca (vključno z EKG).
English: Mexiletine is excreted in human milk.
Slovenian: Meksiletin se izloča v materino mleko.
English: No dosage adjustment is considered necessary in patients with mild or moderate renal impairment.
Slovenian: Pri bolnikih z blago ali zmerno okvaro ledvic ni potrebna prilagoditev odmerka.
English: Very rare: drug-induced liver injury, liver disorder, hepatitis Skin and subcutaneous tissue disorders Common: acne
Slovenian: Zelo redki: z zdravili povzročene poškodbe jeter, bolezni jeter, hepatitis Bolezni kože in podkožja
English: No notable accumulation of mexiletine was observed after repeated administration.
Slovenian: Po ponovnem odmerjanju niso zaznali opaznega kopičenja meksiletina.
English: General disorders and administration site conditions Common: fatigue, asthenia, chest discomfort, malaise
Slovenian: Splošne težave in spremembe na mestu aplikacije Pogosti: utrujenost, astenija, nelagodje v prsih, splošen občutek slabosti
English: Each capsule contains mexiletine hydrochloride corresponding to 166.62 mg mexiletine .
Slovenian: Ena trda kapsula vsebuje meksiletinijev klorid, ki ustreza 166,62 mg meksiletina.
English: Co-administration of mexiletine with a hepatic enzyme inhibitor (CYP1A2 inhibitor: ciprofloxacin, fluvoxamine, propafenone; CYP2D6 inhibitor: propafenone, quinidine) significantly increases mexiletine exposure and thus the associated risk of adverse reactions to mexiletine.
Slovenian: Sočasno jemanje meksiletina in zaviralca jetrnih encimov (zaviralci CYP1A2: ciprofloksacin, fluvoksamin, propafenon; zaviralca CYP2D6: propafenon, kinidin) znatno povečajo izpostavljenost meksiletinu in s tem povezano tveganje za neželene učinke meksiletina.
English: How to store Namuscla 6.
Slovenian: Kako jemati zdravilo Namuscla 4.
English: Poor and extensive CYP2D6 metabolisers
Slovenian: Bolniki s slabo in obsežno presnovo CYP2D6
English: • Co-administration with medicinal products inducing torsades de pointes (see section 4.5)
Slovenian: • Sočasna uporaba z zdravili, ki inducirajo aritmije torsades de pointes (glejte poglavje 4.5)
English: Each hard capsule contains: - mexiletine hydrochloride corresponding to 166.62 mg of mexiletine (active substance) - Other ingredients (maize starch, colloidal anhydrous silica, magnesium stearate, gelatin, iron oxide [E 172], titanium dioxide [E 171]).
Slovenian: Vsaka trda kapsula vsebuje: - meksiletinijev klorid, ki ustreza 166,62 mg meksiletina (učinkovina) - Druge sestavine (koruzni škrob, brezvodni koloidni silicijev dioksid, magnezijev stearat,
English: Not known: leukopenia, thrombocytopenia Immune system disorders
Slovenian: Neznana: levkopenija, trombocitopenija
English: • Reporting of adverse reactions in patients using Namuscla.
Slovenian: • Poročanje o neželenih učinkih pri bolnikih, ki uporabljajo zdravilo Namuscla.
English: Mexiletine should be used with caution in patients with mild or moderate hepatic impairment.
Slovenian: Pri bolnikih z blago ali zmerno okvaro jeter je treba meksiletin uporabljati previdno.
English: Ultra-rapid metabolisers(UM)
Slovenian: Izjemno hitra presnova (IHP)
English: - Transient confusion (a temporary inability to think clearly or concentrate) - Double vision - Altered sense of taste - Disorders of heart rhythm - Collapse - Hot flushes
Slovenian: Eosinophilia and Systemic Symptoms) - halucinacije (prividi in prisluhi) - prehodna zmedenost (začasna nezmožnost jasnega razmišljanja ali koncentracije) - dvojni vid - spremenjen čut za okus - motnje srčnega ritma - kolaps - vročinski oblivi - pljučna fibroza (bolezen pljuč) - driska - bruhanje - poškodbe požiralnika
English: Co-administration of mexiletine with a hepatic enzyme inducer (CYP1A2 inducer: omeprazole; CYP2D6 inducer: phenytoin, rifampicin) may increase the clearance and elimination rate of mexiletine due to an increased hepatic metabolism, resulting in decreased plasmatic concentrations and half-life of mexiletine.
Slovenian: Sočasno jemanje meksiletina in induktorja jetrnih encimov (induktor CYP1A2: omeprazol; induktorja CYP2D6: fenitoin, rifampicin) lahko zaradi povečane jetrne presnove zviša očistek in hitrost izločanja meksiletina, kar vodi v nižje plazemske koncentracije in razpolovno dobo meksiletina.
English: Lupin Europe GmbH Hanauer Landstraße 139-143, 60314 Frankfurt am Main Germany
Slovenian: Lupin Europe GmbH Hanauer Landstraße 139-143, 60314 Frankfurt am Main Nemčija
English: If you have any doubt, ask your doctor or pharmacist.
Slovenian: Če ste v dvomih, se posvetujte z zdravnikom ali farmacevtom.
English: Hormosan Pharma GmbH Hanauer Landstraße 139-143, 60314 Frankfurt am Main Germany
Slovenian: Hormosan Pharma GmbH Hanauer Landstraße 139-143, 60314 Frankfurt am Main Nemčija
English: Namuscla 167 mg hard capsules
Slovenian: Namuscla 167 mg trde kapsule
English: Not known (frequency cannot be estimated from the available data): - Decrease in white blood cells or in platelets - Lupus syndrome (disease of the immune system) - Redness and peeling of the skin - Stevens-Johnson syndrome: a severe allergic reaction with skin rashes, often in the form of blisters and sores in the mouth and eyes, and other mucous membranes - Blisters of the skin, malaise and fever in the context of a condition called DRESS - Hallucinations (seeing or hearing something that is not present).
Slovenian: - pordelost in luščenje kože - Stevens-Johnsonov sindrom: huda alergijska reakcija s kožnim izpuščajem, pogosto v obliki mehurjev in razjed v ustih in očeh ter na drugih sluznicah - mehurji na koži, utrujenost in povišana telesna temperatura v kontekstu sindroma, imenovanega reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS - Drug Reaction with
English: CYP1A2 & CYP2D6 inducers
Slovenian: Induktorji CYP1A2 in CYP2D6
English: • Highlight the risk of decreased Namuscla clearance in patients with hepatic impairment and provide guidance on how to treat those patients in order to prevent it, ensuring Namuscla cautious titration in patients with mild or moderate hepatic impairment (increasing the dose after at least 2 weeks of treatment).
Slovenian: • Poudariti je treba tveganje za zmanjšan očistek zdravila Namuscla pri bolnikih z jetrno okvaro in zagotovite smernice za zdravljenje teh bolnikov, da bi to zmanjšanje preprečili.
English: How to take Namuscla
Slovenian: Kako jemati zdravilo Namuscla
English: Therefore, the use of mexiletine is not recommended in this patient population (see section 4.2).
Slovenian: Uporaba meksiletina zato pri tej populaciji bolnikov ni priporočena (glejte poglavje 4.2).
English: Therefore, the use of mexiletine is not recommended in this patient population (see section 4.4).
Slovenian: Uporaba meksiletina zato pri tej populaciji bolnikov ni priporočena (glejte poglavje 4.4).
English: CYP1A2 & CYP2D6 inhibitors
Slovenian: Zaviralci CYP1A2 in CYP2D6
English: Common: vertigo
Slovenian: Pogosti: navzea
English: Median VAS absolute change from baseline Percentage of Patients with an Absolute VAS Change from Baseline ≥ 50 mm at Day 18 Effect of treatment (Mixed Effect Linear Model)
Slovenian: Srednja vrednost VAS ob izhodišču Srednja vrednost VAS na 18. dan Absolutna sprememba srednje vrednosti VAS glede na izhodišče Odstotek bolnikov z absolutno spremembo srednje vrednosti VAS glede na izhodišče ≥ 50 mm na 18. dan
English: Higher systemic exposure is expected in patients who are CYP2D6 poor metabolisers or who take medicinal products that inhibit CYP2D6 (see section 4.5).
Slovenian: Pri bolnikih, ki slabo presnavljajo CYP2D6 ali jemljejo zaviralce CYP2D6 (glejte poglavje 4.5), je pričakovati višjo sistemsko izpostavljenost.
English: What Namuscla looks like and contents of the pack Namuscla hard capsules are reddish hard gelatin capsules filled with white powder.
Slovenian: Trde kapsule zdravila Namuscla so rdečkaste, trde, želatinaste kapsule, napolnjene z belim praškom.
English: Namuscla should not be used in patients with severe hepatic impairment;
Slovenian: Pri bolnikih s hudo jetrno okvaro se zdravilo Namuscla ne sme uporabljati;
English: Rare: hepatic function abnormal
Slovenian: Redki: motnje delovanja jeter
English: Therefore, mexiletine should not be used in this patient population (see section 4.2).
Slovenian: Uporaba meksiletina zato pri tej populaciji bolnikov ni dovoljena (glejte poglavje 4.2).
English: Namuscla with drink
Slovenian: Zdravilo Namuscla in pijača
English: Mexiletine should be stopped immediately in case any cardiac conduction abnormalities or any of the contraindications listed in the section 4.3 are detected.
Slovenian: Če se pojavi katera koli nepravilnost srčne prevodnosti ali kontraindikacija iz poglavja 4.3, je treba takoj prenehati z jemanjem meksiletina.
English: What Namuscla contains
Slovenian: Kaj vsebuje zdravilo Namuscla
English: • Namuscla should be stopped immediately if the patient develops cardiac abnormalities, is not responding or experiencing benefit within Namuscla long-term treatment;
Slovenian: • Če se pri bolniku pojavijo srčne nepravilnosti, ali če se bolnik ne odziva na zdravljenje, ali ni koristi od dolgotrajnega zdravljenja z zdravilom Namuscla, je treba zdravljenje z zdravilom Namuscla takoj prekiniti;
English: Not known: diarrhoea, vomiting, oesophageal ulcers and perforation Hepatobiliary disorders
Slovenian: Neznana: driska, bruhanje, razjede in perforacija požiralnika Bolezni jeter, žolčnika in žolčevodov
English: BLISTERS
Slovenian: Belci
English: Contact your doctor if you take more than the recommended dose of Namuscla.
Slovenian: Če ste vzeli večji odmerek zdravila Namuscla, kot bi smeli Če ste vzeli večji odmerek zdravila Namuscla, kot je priporočeno, pokličite svojega zdravnika.
English: - liver problems - kidney problems - low or high potassium blood levels - low magnesium blood levels - epilepsy
Slovenian: Pred začetkom jemanja zdravila Namuscla se posvetujte z zdravnikom ali farmacevtom ali medicinsko sestro, če imate: - težave s srcem, - težave z jetri, - težave z ledvicami, - nizko ali visoko koncentracijo kalija v krvi, - nizko koncentracijo magnezija v krvi, - epilepsijo.
English: Smoking and Namuscla
Slovenian: Kajenje in zdravilo Namuscla
English: Every 6 hours
Slovenian: Vsakih 6 ur
English: Every 8 hours
Slovenian: Vsakih 8 ur
English: + Species for which high-resistance rates (more than 50%) have been observed in one or more areas/countries/regions within the EU.
Slovenian: + Vrste za katere je bil opažen visok delež odpornosti (več kot 50 %) v/na enem ali več področij/držav/regij v EU.
English: Unopened vial: 3 years
Slovenian: Zaprte viale: 3 leta
English: The direct Coombs test may be positive.
Slovenian: Direktni Coombsov test je lahko pozitiven.
English: Other microorganisms
Slovenian: Drugi mikroorganizmi
English: No data from controlled clinical studies are available.
Slovenian: Podatkov iz nadzorovanih kliničnih študij ni na voljo.
English: Fertility of the F1 generation and embryonic development of F2 generation were not impaired.
Slovenian: Plodnost F1 generacije in embrionalni razvoj F2 generacij nista bila prizadeta.
English: if you have low levels of potassium in your blood.
Slovenian: če imate nizke vrednosti kalija v krvi.
English: This difference may be due to age-related changes in creatinine clearance.
Slovenian: Ta razlika je lahko posledica starostno pogojenih sprememb v kreatininskem očistku.
English: These reactions are more likely to occur in persons with a history of sensitivity to multiple allergens.
Slovenian: Pojav teh reakcij je verjetnejši pri osebah z anamnezo močne občutljivosti na več alergenov.
English: You will be given TAZOCIN until the sign of infection has gone completely (5 to 14 days).
Slovenian: Zdravljenje z zdravilom TAZOCIN bo trajalo dokler znaki okužbe ne bodo popolnoma izzveneli (od 5 do 14 dni).
English: if you think you developed a new or worsening infection.
Slovenian: če menite, da se je pojavila nova okužba, ali da se je že obstoječa okužba poslabšala.
English: Piperacillin belongs to the group of medicines known as “broad-spectrum penicillin antibiotics”.
Slovenian: Piperacilin spada v skupino zdravil, imenovano “širokospektralni penicilinski antibiotiki”.
English: Do not take any medicine for the diarrhoea without first checking with your doctor.
Slovenian: Ne jemljite nobenih zdravil proti driski, ne da bi se o tem najprej posvetovali s svojim zdravnikom.
English: Possible side effects are listed according to the following categories: - common: affects 1 to 10 users in 100 - uncommon: affects 1 to 10 users in 1,000 - rare: affects 1 to 10 users in 10,000 - very rare: affects less than 1 user in 10,000
Slovenian: Možni neželeni učinki so navedeni v skladu z naslednjimi kategorijami pogostnosti: - pogosti: neželeni učinki, ki se lahko pojavijo pri 1 do 10 od 100 bolnikov - občasni: neželeni učinki, ki se lahko pojavijo pri 1 do 10 od 1.000 bolnikov - redki: neželeni učinki, ki se lahko pojavijo pri 1 do 10 od 10.00 bolnikov - zelo redki: neželeni učinki, ki se lahko pojavijo pri manj kot 1 od 10.000 bolnikov
English: Content of vial
Slovenian: Vsebina viale
English: Tazocin is indicated for the treatment of the following infections in adults and children over 2 years of age (see sections 4.2 and 5.1):
Slovenian: Zdravilo Tazocin je pri odraslih in otrocih, starejših od 2 let, indicirano za zdravljenje naslednjih okužb (glejte poglavji 4.2 in 5.1):
English: Take special care with TAZOCIN if you have allergies.
Slovenian: Bodite posebno pozorni pri uporabi zdravila TAZOCIN če imate alergije.
English: EUCAST Clinical MIC Breakpoints for Piperacillin / Tazobactam (2009-12-02, v 1).
Slovenian: EUCAST klinične mejne vrednosti MIK za piperacilin / tazobaktam (2009-12-02, v 1).
English: From a microbiological point of view, the reconstituted and diluted solutions should be used immediately.
Slovenian: Z mikrobiološkega stališča je treba rekonstituirano in razredčeno raztopino uporabiti takoj.
English: The two main mechanisms of resistance to piperacillin / tazobactam are:
Slovenian: Dva glavna mehanizma odpornosti proti piperacilinu / tazobaktamu sta:
English: For frequency of these reactions, refer to the information below.
Slovenian: Za pogostnost nastanka teh neželenih učinkov, glejte informacije, ki so navedene spodaj.
English: Treatment should be supportive and symptomatic according to the patient's clinical presentation.
Slovenian: Uvesti je treba podporno in simptomatsko zdravljenje, v skladu s kliničnimi znaki pri bolniku.
English: In certain serious infections, your doctor may consider using TAZOCIN in combination with other antibiotics.
Slovenian: V primeru nekaterih hudih okužb lahko zdravnik uporabo zdravila TAZOCIN predpiše v kombinaciji z drugimi antibiotiki.
English: Maximum recommended volume of sterile water for injection per dose is 50 ml.
Slovenian: Največji priporočeni volumen sterilne vode za injekcije je 50 ml na odmerek.
English: A number of chemical urine protein measurement methods may lead to false-positive results.
Slovenian: Številne kemijske metode za določanje proteinov v urinu lahko dajo lažno pozitivne rezultate.
English: Adults and adolescents aged 12 years or older
Slovenian: Odrasli in mladostniki, stari 12 let in starejši
English: * Compatible solvents for reconstitution:
Slovenian: * Kompatibilni vehikli za rekonstitucijo:
English: Please tell your doctor or other healthcare professional if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Slovenian: Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
English: The reconstituted solutions may be further diluted to the desired volume (e.g. 50 ml to 150 ml) with one of the following compatible solvents:
Slovenian: Rekonstituirano raztopino lahko nadaljnje razredčite do želenega volumna (npr. 50 ml do 150 ml) z enim od naslednjih kompatibilnih vehiklov:
English: For Susceptibility Testing Purposes, the Concentration of Tazobactam is Fixed at 4 mg/l
Slovenian: Za namene testiranja občutljivosti, koncentracija tazobaktama je fiksna pri 4 mg/l
English: The intravenous dose should be adjusted to the degree of actual renal impairment as follows (each patient must be monitored closely for signs of substance toxicity; medicinal product dose and interval should be adjusted accordingly):
Slovenian: Intravenski odmerek je treba prilagoditi stopnji dejanske okvare ledvic kot je navedeno v nadaljevanju (vsakega posameznega bolnika je treba skrbno nadzirati glede pojava znakov toksičnosti; odmerek zdravila in odmerni interval je treba ustrezno prilagoditi):
English: Packs containing 1, 5, 10, 12 or 25 vials.
Slovenian: Pakiranja po 1, 5, 10, 12 ali 25 vial.
English: This regimen may also be applicable to treat patients with other indicated infections when particularly severe.
Slovenian: Ta režim odmerjanja se lahko uporabi tudi za zdravljenje bolnikov z drugimi navedenimi okužbami, še posebej, če so okužbe hude.
English: When swirled constantly, reconstitution generally occurs within 5 to 10 minutes (for details on handling, please see below).
Slovenian: Pri neprestanem vrtenju se prašek običajno popolnoma raztopi v 5 do 10 minutah (za podrobnosti o ravnanju z zdravilom glejte spodaj).
English: if you are taking certain medicines (called anticoagulants) to avoid an excess of blood clotting (see also Using other medicines in this leaflet) or any unexpected bleeding occurs during the treatment.
Slovenian: če se zdravite z nekaterimi zdravili (imenovani antikoagulanti), ki preprečujejo nastanek krvnih strdkov (glejte tudi poglavje Uporaba drugih zdravil v tem navodilu), ali če se med zdravljenjem s tem zdravilom pojavi kakršnakoli nepričakovana krvavitev.
English: Paediatric population (2-12 years of age)
Slovenian: Pediatrična populacija (bolniki, stari od 2 do 12 let)
English: No dose adjustment is necessary (see section 5.2).
Slovenian: Okvara jeter Odmerka ni treba prilagajati (glejte poglavje 5.2).
English: Non-depolarising muscle relaxants
Slovenian: Nedepolarizirajoči mišični relaksanti
English: During simultaneous administration of heparin, oral anticoagulants and other substances that may affect the blood coagulation system including thrombocyte function, appropriate coagulation tests should be performed more frequently and monitored regularly.
Slovenian: Pri sočasnem zdravljenju s heparinom, peroralnimi antikoagulanti ali z drugimi zdravili, ki lahko vplivajo na sistem koagulacije krvi, vključno s funkcijo trombocitov, je treba pogosteje opravljati ustrezne teste koagulacije in le-te redno spremljati.
English: What TAZOCIN is and what it is used for Before you use TAZOCIN How to use TAZOCIN Possible side effects
Slovenian: Kaj je zdravilo TAZOCIN in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo TAZOCIN Kako uporabljati zdravilo TAZOCIN Možni neželeni učinki
English: SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM Aerobic Gram-positive micro-organisms
Slovenian: VRSTE PRI KATERIH JE PRIDOBLJENA ODPORNOST LAHKO PROBLEM Aerobni, po Gramu pozitivni mikroorganizmi
English: Effects on laboratory tests
Slovenian: Vplivi na rezultate laboratorijskih preiskav
English: If you notice any of the above, see a doctor straight away.
Slovenian: Če opazite katerikoli zgoraj navedeni neželeni učinek, takoj obiščite zdravnika.
English: WHAT TAZOCIN IS AND WHAT IT IS USED FOR
Slovenian: KAJ JE ZDRAVILO TAZOCIN IN ZA KAJ GA UPORABLJAMO
English: For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.
Slovenian: Za pogoje shranjevanja rekonstituiranega in raztopljenega zdravila glejte poglavje 6.3.
English: In a population PK analysis, estimated clearance for 9 month-old to 12 year-old patients was comparable to adults, with a population mean (SE) value of 5.64 (0.34) ml/min/kg.
Slovenian: Pri populacijski PK analizi je bil ocenjeni očistek pri bolnikih, starih od 9 mesecev do 12 let, primerljiv z očistkom pri odraslih, s populacijsko srednjo (SE) vrednostjo 5,64 (0,34) ml/min/kg.
English: Adult and adolescent patients
Slovenian: Odrasli in mladostniki
English: The most commonly reported adverse reactions (occurring in 1 to 10 patients in 100) are diarrhoea, vomiting, nausea and rash.
Slovenian: Neželeni učinki o katerih so poročali najpogosteje (pri 1 do 10 od 100 bolnikov) so: driska, bruhanje, navzeja in kožni izpuščaj.
English: Haemophilus influenza
Slovenian: Haemophilus influenzae
English: The selection of piperacillin / tazobactam to treat an individual patient should take into account the appropriateness of using a broad-spectrum semi-synthetic penicillin based on factors such as the severity of the infection and the prevalence of resistance to other suitable antibacterial agents.
Slovenian: Pri izbiri kombinacije piperacilin/tazobaktam za zdravljenje posameznega bolnika je treba upoštevati primernost uporabe širokospektralnega polsintetičnega penicilina na osnovi dejavnikov, kot so resnost okužbe in razširjenost odpornosti proti drugim ustreznim antibiotikom.
English: Excessive serum concentrations of either piperacillin or tazobactam may be reduced by haemodialysis (see section 4.4).
Slovenian: Prekomerne koncentracije piperacilina ali tazobaktama se lahko zmanjša s hemodializo (glejte poglavje 4.4).
English: Piperacillin and tazobactam can pass to a baby in the womb or through breast milk.
Slovenian: Piperacilin in tazobaktam lahko preideta na otroka v maternici ali preko materinega mleka.